10% w/v Calcium Gluconate Inj.

Solution for Injection

Calcium is insoluble in adipose tissue and may therefore cause infiltration and subsequent abscess formation, tissue induration and necrosis. After perivascular or superficial IM injection local irritation, possibly followed by skin blanching or tissue necrosis, may occur, see also section "Adverse effects": Extravasation must be avoided; the injection site should be monitored carefully. High Vitamin D intake should be avoided.

Pregnancy and Lactation

Pregnancy:
Calcium passes across the placental barrier and its concentration in fetal blood is higher than in maternal blood. Calcium gluconate injections should be used during pregnancy only if considered to be essential by the physician. The administered dose should be carefully calculated, and the serum calcium level regularly evaluated in order to avoid hypercalcaemia, which may be deleterious for the fetus.

Lactation:
Calcium is excreted in breast milk. This should be borne in mind when administering calcium to women who are breast-feeding their infants.

Interactions

The effects of digoxin and other cardiac glycosides may be potentiated by calcium, which may result in serious toxicity. Therefore, intravenous administration of calcium preparations to patients under therapy with cardiac glycosides is contraindicated. The only exception may be that in calcium administration is imperative for treatment of severe hypocalcaemia symptoms putting the patient at immediate vital risk, if safer therapeutic alternatives are not available and calcium administration via the oral route is not possible (see also sections "Contraindications" and "Special Warnings ..." and "Interactions").

Special warnings and precautions for use

In the exceptional case of IV administration of calcium gluconate to patients receiving cardiac glycosides, adequate cardiac monitoring is mandatory and emergency treatment of cardiac complications such as serious arrhythmias must be available. Calcium salts should only be used with caution and after careful establishment of the indication in patients with nephrocalcinosis, heart diseases, sarcoidosis (Boeck's disease), in patients receiving epinephrine (see section "Interactions"), or in the elderly.

Renal impairment may be associated with hypercalcaemia and secondary hyperparathyroidism. Therefore, to patients with renal impairment, parenteral calcium should be administered only after careful assessment of the indication and the calcium-phosphate balance should be monitored. Solutions containing calcium should be administered slowly to minimise peripheral vasodilatation and cardiac depression. Intravenous injections should be accompanied by heart rate or ECG control because bradycardia with vasodilatation or arrhythmia can occur when calcium is administered too quickly.

In children, 10% w/v Calcium Gluconate Inj. should not be injected IM but only IV. During therapy, serum calcium levels should be monitored closely. Recommended dosage schedule

Adults:
The usual initial dose in adults is 10 ml of 10% w/v Calcium Gluconate Inj., corresponding to 2.26 mmol or 4.5 - 5.5 mEq per litre. Treatment should be aimed at restoring this level. During therapy, serum calcium levels should be monitored closely.

Children and adolescents (< 18 years):
The dose and the route of administration depend on the degree of hypocalcaemia and the nature and severity of the symptoms. In the case of mild and minor muscular symptoms oral calcium administration should be preferred.

Composition

Active substances:
Each 10 ml ampoule contains 940 mg Calcium Gluconate for Injection, equivalent to 2.26 mmol calcium in 10 ml.

Each 1 ml vial contains 94 mg Calcium Gluconate for Injection, equivalent to 0.23 mmol calcium in 1 ml.

Excipients:
Calcium saccharate, water for injections

Pharmaceutical form

Solution for injection

Pharmaco-therapeutic group

Solutions affecting the electrolyte balance: electrolytes.

Indications

Treatment of acute symptomatic hypocalcaemia

Contraindications

10% w/v Calcium Gluconate Inj. must not be administered in the following conditions:
- Hypersensitivity to calcium gluconate and to the excipient,
- Elevated calcium level in blood (hypercalcemia), e.g. in patients with hyperparathyroidism, hyperparathyroidism D, decalcifying malignancies, renal insufficiency, immobilisation osteoporosis, sarcoidosis, milk-alkali syndrome,
- Increased calcium excretion in urine (hypercalciuria),
- Intoxication with cardiac glycosides,
- Therapy with cardiac glycosides.

The only exception may be that IV calcium administration is imperative for treatment of severe hypocalcaemia symptoms putting the patient at immediate vital risk, if safer therapeutic alternatives are not available and calcium administration via the oral route is not possible (see also sections "Contraindications" and "Special Warnings ..." and "Interactions").

Special warnings and precautions for use

In the exceptional case of IV administration of calcium gluconate to patients receiving cardiac glycosides, adequate cardiac monitoring is mandatory and emergency treatment of cardiac complications such as serious arrhythmias must be available. Calcium salts should only be used with caution and after careful establishment of the indication in patients with nephrocalcinosis, heart diseases, sarcoidosis (Boeck's disease), in patients receiving epinephrine (see section "Interactions"), or in the elderly.

Renal impairment may be associated with hypercalcaemia and secondary hyperparathyroidism. Therefore, to patients with renal impairment, parenteral calcium should be administered only after careful assessment of the indication and the calcium-phosphate balance should be monitored. Solutions containing calcium should be administered slowly to minimise peripheral vasodilatation and cardiac depression. Intravenous injections should be accompanied by heart rate or ECG control because bradycardia with vasodilatation or arrhythmia can occur when calcium is administered too quickly.

In children, 10% w/v Calcium Gluconate Inj. should not be injected IM but only IV. During therapy, serum calcium levels should be monitored closely. Recommended dosage schedule

Adults:
The usual initial dose in adults is 10 ml of 10% w/v Calcium Gluconate Inj., corresponding to 2.26 mmol or 4.5 - 5.5 mEq per litre. Treatment should be aimed at restoring this level. During therapy, serum calcium levels should be monitored closely. Recommended dosage schedule

Children and adolescents (< 18 years):
The dose and the route of administration depend on the degree of hypocalcaemia and the nature and severity of the symptoms. In the case of mild and minor muscular symptoms oral calcium administration should be preferred.
The following table gives usual initial dosage values for guidance:

<table>
<thead>
<tr>
<th>Age</th>
<th>Body wt. (kg)</th>
<th>ml</th>
<th>Equiv. to mmol (mEq) calcium</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 mo.</td>
<td>5.5</td>
<td>2 - 5</td>
<td>0.45 - 1.13 (0.9 - 2.26)</td>
</tr>
<tr>
<td>6 mo.</td>
<td>7.5</td>
<td>2 - 5</td>
<td>0.45 - 1.13 (0.9 - 2.26)</td>
</tr>
<tr>
<td>1 yr.</td>
<td>10</td>
<td>2 - 5</td>
<td>0.45 - 1.13 (0.9 - 2.26)</td>
</tr>
<tr>
<td>3 yr.</td>
<td>14</td>
<td>5 - 10</td>
<td>1.13 - 2.26 (2.26 - 4.52)</td>
</tr>
<tr>
<td>7.5 yr.</td>
<td>24</td>
<td>5 - 10</td>
<td>1.13 - 2.26 (2.26 - 4.52)</td>
</tr>
<tr>
<td>12</td>
<td>38</td>
<td>5 - 10</td>
<td>1.13 - 2.26 (2.26 - 4.52)</td>
</tr>
<tr>
<td>&gt; 12 yr.</td>
<td>&gt; 38</td>
<td>as for adults</td>
<td></td>
</tr>
</tbody>
</table>

This corresponds approximately to:
- 0.4 - 5 mmol body weight
- 0.2 - 0.5 mEq/kg body weight
- 0.05 - 0.1 mmol (0.1 - 0.2 mEq) of calcium per kg body weight

For children from 4 to 12 years.

For patients above 12 years of age the adult dosages should be applied.

In cases of severe symptoms of hypercalcaemia, e.g. cardiac symptoms, higher initial doses (up to 2 ml per kg body weight, 0.45 mmol (0.9 mEq) calcium per kg body weight) may be necessary for a quick restoration of a normal serum calcium level.

Always observe, the dose may be repeated, depending on the patient’s clinical condition. Subsequent doses should be adjusted according to the actual serum calcium level.

IV therapy should be followed by oral administration if indicated, e.g. in cases of calciﬁc deﬁciency.

Elderly patients:
Although there is no evidence that tolerance of calcium gluconate injection is directly affected by advanced age, factors that may sometimes be associated with ageing, such as impaired renal function and poor diet, may indirectly affect tolerance and may require a reduction in dosage.

Method of administration

Adults:
Slow intravenous or deep intramuscular injection

Children and adolescents:
Only slow intravenous injection or intravenous infusion after dilution, in order to achieve adequately low administration rates and to avoid intraarteriolescular necrosis in case of accidental extravasation. For intravenous infusion, 10% w/v Calcium Gluconate Inj may be diluted 1:10 to a concentration of 10 mg/ml with the following two infusion fluids: 0.9% w/v Sodium Chloride Intravenous Infusion or 5% w/v Glucose Intravenous Infusion. Intramuscular injections should not be performed in children.

The intravenous administration rate should not exceed 50 mg of calcium gluconate per min. The patient should be in the lying position and should be closely observed during the injection. Monitoring should include heart rate or ECG.

Because of the risk of local irritation, intramuscular injections should only be performed if intravenous injection is not possible. Care should be taken to administer the intramuscular injections sufficiently deep, preferably into the gluteal region. See also sections “Special Warnings” and “Undesirable effects.” In the case of adipose patients a longer needle will have to be chosen for safe positioning of the injection into the muscle and not into adipose tissue. If repeated injections are necessary, the injection site should be changed every time.

Overdose:

Symptoms:
Symptoms of hypercalcaemia may include: anorexia, nausea, vomiting, constipation, abdominal pain, polyuria, polydipsia, dehydration, muscle weakness, bone pain, renal calcification, drowsiness, somnolence, confusion, hypertension and, in severe cases, cardiac arrhythmia up to cardiac arrest, and coma.

If intravenous injection is too rapid, symptoms of hypercalcaemia may occur as well as a chalky taste, hot flushes and hypotension.

Emergency treatment, antidotes:

Treatment should be aimed at lowering the elevated plasma calcium concentration.

Initial management should include rehydration and, if severe hypercalcaemia, it may be necessary to administer sodium chloride by i. v. infusion to expand the extracellular fluid. Calcitonin may be given to lower the elevated serum calcium concentration. Furosemide may be administered to increase calcium excretion but chelate diuretics should be avoided as they may increase renal absorption of calcium. Haemodialysis or peritoneal dialysis may be considered where other measures have failed and where the patient remains acutely symptomatic. Serum electrolytes should be carefully monitored throughout treatment of overdosage.

Undesirable effects

Cardiovascular and other systemic undesirable effects are likely to occur as symptoms of acute hypercalcaemia resulting from IV overdose or too rapid IV injection. Their occurrence and frequency is directly related to the administration rate and the administered dose. Under the conditions of proper administration, they are rare (≤ 1:1000).

Cardiovascular disorders

Hypotension, bradycardia, cardiac arrhythmia, vasodilatation, vasomotor collapse (possibly fatal), flushing, mainly after too rapid injection.

Gastro-intestinal disorders

Nausea, vomiting

General disorders

Heat sensations, sweating

Administration site conditions

Common (≤ 1:10, ≥ 1:100):

Intramuscular injection may be accompanied by pain sensations or erythema.

Adverse reactions only occurring with improper administration technique:

If intramuscular injection is not made at adequate depth, infiltration into the adipose tissue may occur with subsequent abscess formation, tissue induration, and necrosis.

Soft tissue calcification, possibly followed by skin ablation and necrosis, due to extravasation, has been reported.

Reddening of skin, burning sensation or pain during intramuscular injection may indicate accidental perivascular injection, which may lead to tissue necrosis.

Note:

Patients should inform their doctor or pharmacist if they notice any side effect not mentioned in this leaflet.

Expiration date:

The product must not be used beyond the expiry date stated on the labelling.

Instructions for storage / use / handling:

Do not store above 25 °C.

The product is intended for single dose use only. Any unused solution should be discarded immediately after initial use.

Visually inspect the sterile solution for injection for particulate matter or discolouration and the integrity of the container prior to use.

The solution should only be used if it is clear and the container is undamaged.

When diluted according to directions with the recommended infusion fluids, 0.9% w/v Sodium Chloride Intravenous Infusion or 5% w/v Glucose Intravenous Infusion, physical in-use stability has been demonstrated for 48 hours, when stored at room temperature. From a microbiological point of view, the diluted solution should be used within 24 hours of dilution.

Initial management should include rehydration and, in severe hypercalcaemia, the solution may be administered to increase calcium excretion.

Other measures have failed and where the patient remains acutely symptomatic.

Calcitonin may be given to lower the elevated serum calcium concentration. Furosemide may be administered to increase calcium excretion but chelate diuretics should be avoided as they may increase renal absorption of calcium. Haemodialysis or peritoneal dialysis may be considered where other measures have failed and where the patient remains acutely symptomatic. Serum electrolytes should be carefully monitored throughout treatment of overdosage.

Cardiovascular and other systemic undesirable effects are likely to occur as symptoms of acute hypercalcaemia resulting from IV overdose or too rapid IV injection. Their occurrence and frequency is directly related to the administration rate and the administered dose. Under the conditions of proper administration, they are rare (≤ 1:1000).

Cardiovascular disorders

Hypotension, bradycardia, cardiac arrhythmia, vasodilatation, vasomotor collapse (possibly fatal), flushing, mainly after too rapid injection.

Gastro-intestinal disorders

Nausea, vomiting

General disorders

Heat sensations, sweating

Administration site conditions

Common (≤ 1:10, ≥ 1:100):

Intramuscular injection may be accompanied by pain sensations or erythema.

Adverse reactions only occurring with improper administration technique:

If intramuscular injection is not made at adequate depth, infiltration into the adipose tissue may occur with subsequent abscess formation, tissue induration, and necrosis.

Soft tissue calcification, possibly followed by skin ablation and necrosis, due to extravasation, has been reported.

Reddening of skin, burning sensation or pain during intramuscular injection may indicate accidental perivascular injection, which may lead to tissue necrosis.

Note:

Patients should inform their doctor or pharmacist if they notice any side effect not mentioned in this leaflet.

Expiration date:

The product must not be used beyond the expiry date stated on the labelling.

Instructions for storage / use / handling:

Do not store above 25 °C.

The product is intended for single dose use only. Any unused solution should be discarded immediately after initial use.

Visually inspect the sterile solution for injection for particulate matter, discolouration and the integrity of the container prior to use.

The solution should only be used if it is clear and the container is undamaged.

When diluted according to directions with the recommended infusion fluids, 0.9% w/v Sodium Chloride Intravenous Infusion or 5% w/v Glucose Intravenous Infusion, physical in-use stability has been demonstrated for 48 hours, when stored at room temperature. From a microbiological point of view, the diluted product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not exceed 24 hours at 2 to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

Date of last revision: 06.2005